Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Futura MedicalFAMDF +4.00% Capex-to-Operating-Cash-Flow is 0.00 as of Jun. 2026. The stock has 5 warning signs investors should review. Among 241 Biotechnology companies, Futura Medical ranks worse than 414937.34% on this metric.
Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.
Futura Medical (OTCPK:FAMDF) Capex-to-Operating-Cash-Flow Explanation
Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.
Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.
Futura Medical Capex-to-Operating-Cash-Flow Related Terms
Futura Medical Capex-to-Operating-Cash-Flow Historical Data
* Premium members only.
The historical data trend for Futura Medical's Capex-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FAMDF vs VRTX, REGN, MRNA: Capex-to-Operating-Cash-Flow Comparison
For the Biotechnology subindustry, Futura Medical's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Futura Medical Capex-to-Operating-Cash-Flow vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Futura Medical's Capex-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Futura Medical's Capex-to-Operating-Cash-Flow falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Capex-to-Operating-Cash-Flow of 0.00 mean?
Futura Medical (FAMDF) has a Capex-to-Operating-Cash-Flow of 0.00 as of Jun. 2026. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on Futura Medical and its competitors. Over the past decade, Futura Medical's Capex-to-Operating-Cash-Flow has ranged from 2.64 to 4.42. According to the industry distribution chart, Futura Medical ranks #999999 out of 241 companies in the Biotechnology industry.
Is Futura Medical's Capex-to-Operating-Cash-Flow too high?
Futura Medical's current Capex-to-Operating-Cash-Flow is 0.00. Over the past 10 years, this metric has ranged from a low of 2.64 to a high of 4.42. Based on the distribution chart, Futura Medical ranks #999999 out of 241 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Futura Medical's Capex-to-Operating-Cash-Flow compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Futura Medical ranks #999999 out of 241 companies for Capex-to-Operating-Cash-Flow. This places Futura Medical in the lower half of its industry. The industry median Capex-to-Operating-Cash-Flow is 0.35. Historically, Futura Medical's own Capex-to-Operating-Cash-Flow has ranged from 2.64 to 4.42 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Operating-Cash-Flow for a Biotechnology company?
The median Capex-to-Operating-Cash-Flow among Biotechnology companies is 0.35, based on 241 companies in the industry. Companies in the top quartile (top 25%) have a Capex-to-Operating-Cash-Flow significantly above this median, while those in the bottom quartile fall well below. However, Capex-to-Operating-Cash-Flow should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Operating-Cash-Flow mean?
A high Capex-to-Operating-Cash-Flow can signal that a stock is expensive relative to its fundamentals. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on Futura Medical and its competitors. For the Biotechnology industry, the median Capex-to-Operating-Cash-Flow is 0.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Futura Medical's current Capex-to-Operating-Cash-Flow is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Futura Medical stock overvalued right now?
Futura Medical (FAMDF) has a current Capex-to-Operating-Cash-Flow of 0.00. The current Capex-to-Operating-Cash-Flow is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Operating-Cash-Flow calculated?
Capex-to-Operating-Cash-Flow is calculated from a company's financial statements. For Futura Medical (FAMDF), the current Capex-to-Operating-Cash-Flow is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Futura Medical PLC is engaged in the development and commercialization of sexual health products. Its product Eroxon is a treatment for erectile dysfunction. Geographically, the company derives the majority of its revenue from the United Kingdom and the European Union.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FAMDF has been successfully added to your 
